Radiopharm Theranostics (NASDAQ: RADX) files 6-K with EGM notice

Rhea-AI Filing Summary

Radiopharm Theranostics Limited furnished a Form 6-K to provide U.S. investors with access to a public notice it released on the Australian Securities Exchange. The notice is titled “Notice of Extraordinary General Meeting and Proxy Form” and relates to an upcoming shareholder meeting and associated voting materials. The full notice and proxy form are attached as an exhibit to this report, but are not treated as filed for purposes of the U.S. Securities Exchange Act or automatically incorporated into other U.S. securities filings.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 11/04/2025 - 08:00 AM Learn about SEC filing dates

FAQ

What did Radiopharm Theranostics (RADX) submit in this Form 6-K?

Radiopharm Theranostics submitted a Form 6-K that furnishes a copy of its Australian Securities Exchange announcement titled “Notice of Extraordinary General Meeting and Proxy Form.”

What is the main purpose of this Radiopharm Theranostics (RADX) 6-K?

The main purpose is to make the extraordinary general meeting notice and proxy form, previously published on the Australian Securities Exchange, available to U.S. investors as an exhibit.

Does this Radiopharm Theranostics (RADX) 6-K incorporate the meeting materials into other U.S. filings?

No. The company states that this report shall not be deemed to be “filed” for Exchange Act purposes and shall not be incorporated by reference into Securities Act filings unless specifically referenced.

What document is attached as an exhibit to the Radiopharm Theranostics 6-K?

The 6-K includes one exhibit labeled 99.1, described as the “Notice of Extraordinary General Meeting and Proxy Form.”

Who signed this Radiopharm Theranostics (RADX) Form 6-K?

The Form 6-K was signed on behalf of Radiopharm Theranostics Limited by Phillip Hains, who is identified as the Company Secretary.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of November 2025

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐       No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published an announcement (the “Public Notice”) to the Australian Securities Exchange on November 4, 2025 titled:

“Notice of Extraordinary General Meeting and Proxy Form”  

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit Number		Description
99.1		Notice of Extraordinary General Meeting and Proxy Form

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: November 4, 2025	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

3